rs3796508 — TLR6 Val327Met

Missense variant substituting valine with methionine at position 327 of TLR6, predicted damaging by SIFT and PolyPhen; the Met327 allele is rare globally but reaches 6% in East Asian populations and alters TLR2/TLR6 heterodimer function, affecting diacylated lipopeptide recognition from bacteria and mycoplasma with downstream consequences for innate immune regulation and autoimmune-inflammatory risk

See your personal result for TLR6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TLR6 Val327Met — A Rare Damaging Variant in the Mycoplasma Alarm System

Every time your immune cells encounter diacylated lipopeptides — the molecular calling-card of mycoplasma, staphylococcal lipoproteins, and certain gram-positive bacteria — they rely on a precise molecular handshake between Toll-like Receptor 2 (TLR2)11 Toll-like Receptor 2 (TLR2)
TLR2 is the central scaffold for bacterial lipopeptide sensing; it forms heterodimers with either TLR1 (for triacylated lipopeptides) or TLR6 (for diacylated lipopeptides), activating NF-κB and driving TNF-α, IL-6, and IL-12 production and TLR622 TLR6
Toll-like Receptor 6, encoded at chromosome 4p14; forms obligate heterodimers with TLR2 and is distinguished from TLR1 by a blocked lipid channel that restricts ligand recognition to diacylated — not triacylated — lipopeptides. The rs3796508 Val327Met variant substitutes a structurally conservative valine with a bulkier, polar methionine at position 327 in TLR6's extracellular leucine-rich repeat (LRR) domain — a change that SIFT and PolyPhen independently predict to be damaging to protein function.

This variant is extremely rare in European populations (T allele ~0.2%) but reaches a frequency of approximately 6% in East Asian populations (gnomAD), making it clinically relevant primarily for individuals of East Asian ancestry. It has no ClinVar entry, but published functional predictions and emerging association data across multiple disease contexts — colorectal cancer, allergic rhinitis, smoking-related disease — consistently point to meaningful functional consequences in the TLR2/TLR6 signaling arm of innate immunity. Its placement here in the autoimmune-inflammation category captures TLR6's role not only in infectious defense but in the chronic, low-grade inflammatory processes that contribute to autoimmune pathology.

The Mechanism

The 2009 crystal structure of the TLR2/TLR6 heterodimer (Kang et al., Immunity 200933 Kang et al., Immunity 2009
PMID 19931471; first crystal structure of TLR2/TLR6 bound to diacylated lipopeptide; determined at 2.1 Å resolution) revealed the molecular basis for TLR6's unique specificity. Unlike TLR1, which accommodates a third fatty acid chain in an open lipid channel, TLR6 has its corresponding channel blocked by two conserved phenylalanines — physically preventing triacylated lipopeptide binding and enforcing diacylated specificity. When these phenylalanines are mutated, TLR2/TLR6 loses its diacyl-exclusivity. The compensating structural feature is a dimerization interface that is 80% larger than TLR2/TLR1, stabilising the heterodimer through extensive hydrophobic contacts in the absence of a full three-chain lipid anchor.

Position 327 falls within the leucine-rich repeat domain of TLR6 that forms part of this enlarged dimerization interface and contributes to the extracellular geometry that coordinates diacylated lipopeptide presentation. Valine at position 327 is a hydrophobic residue well-suited to packing into the hydrophobic dimerization interface; methionine is larger and introduces a flexible sulphur-containing side chain. The Val327Met substitution likely perturbs local packing of the LRR domain, potentially altering the geometry of TLR2/TLR6 heterodimer assembly and reducing signaling efficiency upon ligand engagement. SIFT (deleterious) and PolyPhen-2 (probably damaging) predictions, reported in the colorectal cancer association study by Semlali et al. 201944 Semlali et al. 2019
PMID 31281474, support the inference of functional disruption.

The Evidence

Compared to TLR6 Ser249Pro (rs5743810) — the more extensively studied variant in the same gene — rs3796508 Val327Met has a much smaller published literature, and no study has directly measured the impact of Met327 on TLR2/TLR6 heterodimer formation or NF-κB activation in primary cells. The evidence base is emerging and largely association-derived.

The most direct disease association comes from a Saudi Arabian colorectal cancer case-control study55 colorectal cancer case-control study
115 CRC cases, 102 healthy controls; genotyped by TaqMan assay by Semlali et al. (2019). In the global analysis, rs3796508 showed no significant association with CRC risk overall, but in subgroup analyses the Val/Met heterozygous genotype demonstrated a protective effect in males (OR=0.095, p=0.034) and in individuals over 57 years66 protective effect in males (OR=0.095, p=0.034) and in individuals over 57 years
these are suggestive findings from a small study (n=217) and require independent replication. The same paper noted that TLR6 expression was significantly reduced in colon cancer tissue versus normal colon (p<0.001), positioning TLR6 as a potential tumour-suppressive innate immune sensor in the gut. Reduced TLR2/TLR6 signalling from Met327 could plausibly impair this innate surveillance.

In an inflammatory context, a 2026 Chinese Han study (Wang et al., Sci Rep 202677 Wang et al., Sci Rep 2026
PMID 41663697; 992 AR patients versus 992 healthy controls; primary focus on NFKB1 variants with TLR6 rs3796508 as a secondary finding) found that rs3796508 contributed to increased allergic rhinitis (AR) risk specifically in women. This sex-specific effect is consistent with reports of sex-dimorphic TLR6 phenotypes in other variants (notably rs5743810 Ser249Pro, where cardiovascular and leprosy associations show sex-specific patterns). The AR finding is notable because it suggests Met327 may shift TLR2/TLR6 responses in a direction that promotes type-2 (Th2) allergic inflammation — potentially through altered NF-κB dynamics that affect the Th1/Th2 balance during early immune development and sensitisation.

A smoking study (Kohailan et al., Onco Targets Ther 201688 Kohailan et al., Onco Targets Ther 2016
PMID 27920557; 177 smokers vs 126 non-smokers; Saudi population) examined rs3796508 among TLR6 variants in smokers, proposing the Val327Met variant as a potential index for smoking-related disease susceptibility. Tobacco smoke contains lipopolysaccharide- and lipopeptide-like compounds that chronically activate TLR2/TLR6; a damaging variant at position 327 could blunt this response — a mechanism consistent with altered inflammatory signalling in smoking-exposed airways.

Practical Implications

The evidence for rs3796508 is emerging and requires cautious interpretation. The variant is predicted damaging by two independent computational tools, which provides a biological prior for functional effects on TLR2/TLR6 signalling. However, no functional cellular studies have directly measured NF-κB output, cytokine production, or heterodimer formation efficiency in cells carrying the Met327 allele — these experiments are needed to validate computational predictions.

For carriers — predominantly individuals of East Asian descent (~6%) where the variant reaches population significance — the actionable implications centre on monitoring contexts where TLR2/TLR6 competence matters: gut barrier function (TLR6 plays a role in colonic innate surveillance), respiratory allergy (sex-specific AR risk increase in women), and chronic inflammatory conditions where TLR2/TLR6 pathway tone modulates disease expression.

The TLR2/TLR6 pathway also serves as a critical interface between commensal gut bacteria and mucosal immune regulation. The beneficial gut bacterium Faecalibacterium prausnitzii99 Faecalibacterium prausnitzii
a major short-chain fatty acid producer and key modulator of gut immune homeostasis; low in IBD patients signals through TLR2/TLR6 to prime regulatory T cells — a pathway that could be impaired by reduced Met327 signalling.

Interactions

TLR6 operates exclusively through TLR2 (rs5743708). The TLR2 R753Q variant independently impairs TLR2 signalling from the intracellular TIR domain; any individual carrying both rs5743708 (TLR2 R753Q) and rs3796508 (TLR6 Val327Met) faces potential compound reduction of TLR2/TLR6 output from two separate structural points. The Ser249Pro variant (rs5743810) in TLR6 modulates NF-κB activation efficiency from the extracellular domain; individuals with both rs3796508 and rs5743810 risk alleles on the same TLR6 molecule (in cis) would carry two independent damaging changes in the same receptor — a scenario that warrants investigation in populations where both alleles are present (East Asian populations carry both at detectable frequencies). TLR1 (rs5743618) handles the triacylated lipopeptide arm of pattern recognition and operates independently of TLR6.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard TLR6 Function Normal

Common TLR6 Val327 homozygote with standard diacylated lipopeptide sensing

You carry two copies of the valine-327 allele at TLR6 — the common form shared by approximately 98.7% of people globally. Your TLR2/TLR6 heterodimer is predicted to assemble normally and to respond to diacylated lipopeptides from mycoplasma and gram-positive bacteria at baseline efficiency. No disease associations have been identified for this genotype at rs3796508.

CT Val/Met TLR6 Heterozygote Intermediate

One Met327 allele — predicted damaging to TLR2/TLR6 heterodimer signaling; emerging associations with reduced innate sensing efficiency

Position 327 sits in the leucine-rich repeat (LRR) extracellular domain of TLR6 that contributes to the enlarged hydrophobic heterodimer interface with TLR2. The valine-to-methionine change introduces a bulkier, flexible side chain that computational models predict disrupts local packing at this interface.

The two published disease associations for this variant operate in apparently opposite directions — protective against colorectal cancer (in males) but potentially risk-increasing for allergic rhinitis (in females). These apparently contradictory findings may reflect genuine sex-specific effects (TLR6 shows established sex dimorphism in other variants, particularly rs5743810), differences in whether reduced TLR2/TLR6 activity is protective (limiting chronic gut inflammation) or harmful (impaired epithelial antimicrobial surveillance, shifted Th1/Th2 balance toward atopy). Both findings come from small studies and neither has been independently replicated — they define the hypothesis-generating stage of evidence for this variant.

No functional cell-based data yet exists measuring NF-κB activation, cytokine output, or TLR2/TLR6 heterodimer stability in Met327 carrier cells directly.

TT Met/Met TLR6 Homozygote Reduced

Two Met327 alleles — both copies of TLR6 carry the damaging variant, with predicted significant reduction in TLR2/TLR6 heterodimer signaling

Homozygous carriers of predicted-damaging missense variants in TLR6 face disruption of TLR2/TLR6 signalling from both copies of the receptor. Based on the structural model (TLR6 LRR domain packing at position 327 contributing to the TLR2/TLR6 hydrophobic dimerization interface), both receptor copies would carry the destabilising methionine substitution. The downstream consequences for NF-κB activation, TNF-α/IL-6 production, and inflammatory regulation in response to TLR2/TLR6 agonists are likely more pronounced than in heterozygotes.

The potential consequences span several biological axes: (1) impaired innate sensing of mycoplasma and diacylated lipopeptide-bearing bacteria; (2) reduced TLR2/TLR6-mediated gut epithelial surveillance (relevant to colorectal inflammation and cancer risk); (3) possible shift toward atopic (Th2) immune responses if the Th1-promoting output of TLR2/TLR6 is substantially blunted; (4) altered regulation of the gut-mucosal immune axis, including impaired Faecalibacterium prausnitzii-mediated TLR2/TLR6 induction of regulatory T cells.

This genotype is sufficiently rare (estimated <1 in 1,000) that no published study has reported a TT homozygote sub-analysis. All current associations derive from CT heterozygote data.